Well-known for acquisitions-led growth strategy, Nicholas Piramal India Limited aims to be No.1 player in the domestic market and a world leader in customer manufacturing.
Nicholas Piramal India Limited (Nicholas Piramal), one of India's leading pharmaceutical companies, has a rich tradition of partnering with global pharmaceutical players. Over the last 16 years, Nicholas Piramal has concluded nine successful acquisitions that include the Indian subsidiaries of MNCs like Roche, Boehringer Mannheim, Rhone Poulenc, Hoechst Marion Roussel (research division), and the pharmaceutical division of ICI India limited. Each acquisition had a strategic reasonto get access to new products, or get entry into a fast-growing therapeutic segment. Thus, within a short span of 16 years, through a string of mergers and acquisitions, Nicholas Piramal emerged as India's second largest pharmaceutical company in branded formulation segment. It has 4.4% share in the domestic market and has a dominating presence in nine therapeutic areas, which forms about 90% of Indian pharmaceutical market. With 3074 sales people, the company has the largest field force in the industry. In 2003-04, its revenues stood at Rs. 12.7 bn and profit at Rs. 1.9 bn. An impressive 92% of its revenues comes from domestic market. But Nicholas Piramal, which is known for its strength in managing growth through acquisition in the domestic market, has moved on to exports, thus adding a new dimension to its revenue stream. In FY04, Nicholas Piramal has implemented a differentiated exports strategy, which is built on partnership with global innovator companies for long-term custom manufacturing contracts. Nicholas Piramal aspires to have 50% of the sales coming from exports at the end of the next five years. |
